Pfizer: The vaccine is effective in 95%, we can supply 50 million doses by the end of the year

November 18, 2020   

The American pharmaceutical company Pfizer reported today (Wednesday) that it has completed the third phase of the coronavirus vaccine trial with extremely positive results - 95% efficacy and less than 2% mild side effects. Have you been suffering from depression lately? Are you eligible for National Insurance?’ The company said its vaccine would be submitted to the authorities for approval within days. Pfizer said that if the FDA approves the two-dose vaccine, it could supply up to 50 million doses by the end of this year, and another 1.3 billion doses by the end of next year. Last week, Pfizer reported that preliminary results from the trial showed the vaccine to be more effective than 90%. Moderna released preliminary data for its vaccine on Monday, showing the effectiveness of 95%.